Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The global hereditary angioedema (HAE) market, by drug class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By route of administration (Subcutaneous, Intravenous, and Oral), by distribution channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) and by region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa), had accounted for US$ 1,563.7 million in 2016, and is now projected to exhibit a robust CAGR of 9.1% over the forecast period (2017-2025).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1292
The global hereditary angioedema market is foreseen to gain magnificent traction in the near future, with the increasing product innovations and development of novel drugs by the key manufacturers in this market, further supported by increasing R&D initiatives taken by several research foundations. Also, novel delivery platforms adopted by these manufacturers are expected to accelerate the global market growth over the projected timeframe.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1292
Positive clinical trial results integrated with assured safety profiles to cater to the unmet requirements of this disease are projected to augment the global hereditary angioedema market. For instance, in 2016, Arrowhead Pharmaceuticals’ RNAi-based candidate ARC-F12 by underwent preclinical development and went to become a potential treatment for factor XII (F12)-mediated diseases. Furthermore, the novel gene therapy product candidate, known as AADVM-053, introduced by Adverum Biotechnologies, underwent the preclinical trials for the treatment of patients HAE. ADVM-053, for the record, is an Adeno Associated Virus (AAV)-based gene transfer vector aimed at providing persistent levels of human C1-esterase inhibitor (C1-INH) to potentially correct the deficiency state, which often results in life-threatening attacks.
Key Takeaways:
- The global hereditary angioedema market is expected to exhibit a CAGR of 9.1% over the forecast period, owing to the presence of high potential markets and surging awareness of the condition in regions, including Europe, Asia Pacific, and Latin America.
- Based on drug class, the C1 esterase inhibitor segment dominates the global hereditary angioedema market, in terms of market share, owing to the robust number of drugs approved by the regulatory agencies.
Browse Press Release: https://bit.ly/36nHPhx
Competitive Backdrop:
CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies and Attune Pharmaceuticals, Inc. are some of the leading companies operating in the global hereditary angioedema market.
These players have been implementing strategic collaborations and acquisitions for the development and expansion of their HAE portfolio. For instance, in January 2018, BioCryst Pharmaceuticals and Idera Pharmaceuticals merged to create a new rare-disease company. The companies currently have two phase 3 clinical compounds, including BioCryst’s BCX7353 and Idera’s IMO-8400.
Furthermore, in 2015, Shire Plc acquired Dyax Corp. in order to get access and achieve worldwide sales of lead pipeline product DX-2930, Phase 3-ready, fully-humanized monoclonal antibody. The FDA granted DX-2930 fast track, breakthrough therapy, and orphan drug designation in the EU.
Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1292
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
